Andrew Billnitzer, MD

Assistant Professor of Clinical Neurology, Academic Institute
Assistant Clinical Member, Research Institute
Houston Methodist


A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
PASADENA Investigators & Prasinezumab Study Group 2021, , Frontiers in Neurology, vol. 12, 705407.

Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome
Billnitzer, A & Jankovic, J 2021, , Movement Disorders Clinical Practice, vol. 8, no. 5, pp. 694-700.

Generalized Periodic Discharges With Triphasic Morphology in the Setting of Aztreonam Neurotoxicity
Billnitzer, A & Kaplan, PW 2021, , Clinical EEG and Neuroscience, vol. 52, no. 1, pp. 66-68.

Parkinson's disease and skin
Niemann, N, Billnitzer, A & Jankovic, J 2021, , Parkinsonism and Related Disorders, vol. 82, pp. 61-76.

The clinical value of patient home videos in movement disorders
Billnitzer, A & Jankovic, J 2021, , Tremor and Other Hyperkinetic Movements, vol. 11, 37.

Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments
Billnitzer, A & Jankovic, J 2020, , Neurotherapeutics, vol. 17, no. 4, pp. 1681-1693.

Subacute Encephalopathy With Seizures in Alcoholics (SESA) Presenting as Focal Nonconvulsive Status Epilepticus
Kaplan, PW, Billnitzer, A & Fernández-Torre, JL 2018, , Clinical EEG and Neuroscience, vol. 49, no. 6, pp. 414-416.

APP independent and dependent effects on neurite outgrowth are modulated by the receptor associated protein (RAP)
Billnitzer, AJ, Barskaya, I, Yin, C & Perez, RG 2013, , Journal of Neurochemistry, vol. 124, no. 1, pp. 123-132.